The Genomics Core Facility is a newly proposed core that will perform high throughput analyses of genetic (polymorphism/mutations) and epigenetic various (DNA methylation) that underlie predisposition and progression to cancer. The Core will use the latest technology to evaluate primarily genetic variations for association studies using single nucleotide polymorphisms (SNPs). SNPs represent the most commonly occurring DNA sequence variations in the human genome and within several years these polymorphisms will be present at a density of 1 every 1-2 kb. A dense set of these markers can be used to identify genetic factors associated with complex disease traits. These analyses can be performed to investigate germline genetic changes giving rise to hereditary or familial cancer and to investigate somatic genetic changes that are hallmarks of clonal expansion in tumors. In addition, the Core will provide methods for evaluating the genetic the inheritance of information on the basis of epigenetics. DNA methylation is the only epigenetic mark preserved in genomic DNA isolated from tumors or biopsies. The large number of studies documenting associations between methylation patterns and gene expression suggest that the DNA methylation pattern of a cell may represent a rough blueprint for the expression profile of that cell. In addition, the use of genetically modified mice as models for cancer and tumorigenesis will be supported by the Genomics Core Facility by genotyping mouse progeny in conjunction with the Transgenic Core Facility to follow genetic markers during mating. The new Core Facility will utilize expertise in epidemiologic/population studies and DNA methylation present within the Cancer Center projects and providing resources for future initiatives. Finally, it is envisioned that future development in gene chip array technology will be utilized to assess multiple SNPs simultaneously. Analysis of such DNA SNP arrays will be performed by the Microarray Core Facility; however DNA and template preparations for this purpose will still be performed by the Genomics Core Facility.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014089-27
Application #
6563680
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2001-12-01
Project End
2002-11-30
Budget Start
Budget End
Support Year
27
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Liu, Minmin; Zhang, Lian; Li, Hongtao et al. (2018) Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma. Hepatology 68:1412-1428
Miller, Kimberly A; Ramirez, Cynthia N; Wojcik, Katherine Y et al. (2018) Prevalence and correlates of health information-seeking among Hispanic and non-Hispanic childhood cancer survivors. Support Care Cancer 26:1305-1313
Belic, Jelena; Graf, Ricarda; Bauernhofer, Thomas et al. (2018) Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. Int J Cancer 143:1236-1248
Tobin, Jessica; Allem, Jon-Patrick; Slaughter, Rhona et al. (2018) Posttraumatic growth among childhood cancer survivors: Associations with ethnicity, acculturation, and religious service attendance. J Psychosoc Oncol 36:175-188
Schaal, Justin B; Maretzky, Thorsten; Tran, Dat Q et al. (2018) Macrocyclic ?-defensins suppress tumor necrosis factor-? (TNF-?) shedding by inhibition of TNF-?-converting enzyme. J Biol Chem 293:2725-2734
Iriondo, Oihana; Liu, Yarong; Lee, Grace et al. (2018) TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun 9:1994
Robison, Nathan J; Yeo, Kee Kiat; Berliner, Adrian P et al. (2018) Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. J Neurooncol 138:199-207
Naseem, Madiha; Barzi, Afsaneh; Brezden-Masley, Christine et al. (2018) Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 66:15-22
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472

Showing the most recent 10 out of 842 publications